FinlandFinland

Agreement Worth $13.2 Million

06.08.2004

Turku - Biotie Therapies Corp. has recently signed a cooperation and option agreement with Somaxon Pharmaceuticals Inc., San Diego. Under the terms of the agreement Somaxon has an option to an exclusive license for North American rights to develop, manufacture and market Nalmefene for the treatment of pathological gambling and other impulse control disorders. Somaxon has paid BioTie $0.2 million as an initial option fee in July. Upon gaining a clinical development agreement with FDA, the companies will execute the license agreement and BioTie will receive a $3 million signing fee. Additionally, BioTie can receive clinical development milestone payments totaling $10 million plus royalties on sales in North America. Nalmefene is a specific and selective opioid receptor antagonist, which has demonstrated safety and efficacy in a phase II clinical study in the US in patients suffering from pathological gambling and in two phase III studies in the UK and in Finland in patients suffering from alcoholism and alcohol abuse.

FinlandFinland

11.02.2011

Helsinki – Using laser light to destroy tumour cells lodged in lymphatic vessels can halt the spread of cancer, Finnish researchers headed by Tuomas Tammela have demonstrated. Their approach to destroy the tumour cells, which use...

FinlandFinland

03.11.2010

Turku/Freiburg – EU researchers led by scientists at the University of Turku have begun designing a bacterium able to produce liquefied petroleum gas (LPG) from sunlight. “We have all the parts to put the ability for production...

FinlandFinland

19.09.2010

Rajamäki/Darmstadt – A cooperation project between AB Enzymes Oy and Royal Oy has resulted in the discovery of an enzyme that enables washing temperature to be dropped to as low as 10° C. The project is being funded by the SymBio...

FinlandFinland

08.07.2010

Turku – Finland’s Faron Pharmaceuticals Ltd. has announced a cooperation with German biotech company Priaxon AG to create new scaffold structures to modify the AOC3-protein function and its ligand interaction with orally...

FinlandFinland

09.06.2010

Tampere – Short people are at greater risk of developing heart disease than tall people, according to a meta-analysis of 52 populations-based studies including 3 million people by Finnish researchers (Eur. Heart J.,...

FinlandFinland

12.05.2010

Reykjavik – Researchers from the Icelandic bio­tech company deCODE – together with colleagues from 23 institutions in a dozen countries – have determined that genetic factors influence both nico­tine dependence and the incidence...

FinlandFinland

11.05.2010

Turku – Finnish Biotie Therapies Corp. confirmed that its oral phospho­diesterase 4 inhibitor ELB353 has proven safe and pharmacologically active in a Phase I study. Pharmacokinetic data point to the suitability of ELB353 for a...

FinlandFinland

07.03.2010

Helsinki/Hinxton – Finland has pledged EUR1.85m to help create world-class bio­informatics, biobanking and translational research infrastructures, the European Bioinformatics Institute (EBI) at the European Molecular Laboratory...

FinlandFinland

04.02.2010

Helsinki –Finland is investing EUR1.9m in creating world class bioinformatics, biobanking and translational research infrastructures. The investment comes as part of the linkage of three large EU projects ELIXIR, BBMRI, and...

Displaying results 11 to 20 out of 96

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/1/article/agreement-worth-132-million.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR221.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK49.8%
  • Allergy Therapeutics (UK)20.00 GBP33.3%

FLOP

  • HYBRIGENICS (F)1.68 EUR-28.5%
  • METABOLIC EXPLORER (F)2.88 EUR-21.3%
  • VITA 34 (D)4.16 EUR-20.6%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR290.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.0%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-71.0%

No liability assumed, Date: 01.08.2014


Current issue

All issues

Product of the week

Products